Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 65 Records) |
| Query Trace: Lung Neoplasms and HLA-B[original query] |
|---|
| HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 9 16 (1): 104-112. Dimou Anastasios, Grewe Paul, Sidney John, Sette Alessandro, Norman Paul J, Doebele Robert |
| Genetic variants in the human leukocyte antigen region and survival of Chinese patients with non-small cell lung carcinoma. Carcinogenesis 2020 Jul . Cheng Lei, Liu Qi, Wang Mengyun, Gu Yanzi, Wang Jialei, Wei Qingyi, Zhang Ruox |
| HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology 2020 Apr . Shim J H, Kim H S, Cha H, Kim S, Kim T M, Anagnostou V, Choi Y-L, Jung H A, Sun J-M, Ahn J S, Ahn M-J, Park K, Park W-Y, Lee S |
| Difference of copy number variation in blood of patients with lung cancer. The International journal of biological markers 2020 Dec 1724600820980739. Heo Yeonjeong, Heo Jeongwon, Han Seon-Sook, Kim Woo Jin, Cheong Hyun Sub, Hong Yoon |
| Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy. Journal for immunotherapy of cancer 2020 Nov 8 (2): . Abed Afaf, Calapre Leslie, Lo Johnny, Correia Suzana, Bowyer Samantha, Chopra Abha, Watson Mark, Khattak Muhammad Adnan, Millward Michael, Gray Elin Solomonov |
| Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. Cancer discovery 2020 10 11 (2): 282-292. Montesion Meagan, Murugesan Karthikeyan, Jin Dexter X, Sharaf Radwa, Sanchez Nora, Guria Ameet, Minker Max, Li Gerald, Fisher Virginia, Sokol Ethan S, Pavlick Dean C, Moore Jay A, Braly Alan, Singal Gaurav, Fabrizio David, Comment Leah A, Rizvi Naiyer A, Alexander Brian M, Frampton Garrett M, Hegde Priti S, Albacker Lee |
| Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy. Heliyon 2021 9 7 (9): e07916. Lee Dongyup, Park Jonghanne, Choi Horyun, Gim Gahyun, Cho Sukjoo, Kim Leeseul, Oh Youjin, Kang Cyra Y, Kim Yeseul, Tan Dean, de Viveiros Pedro Antonio Hermida, Chae Young Kwa |
| The prevalence of HLA-I LOH in Chinese pan-cancer patients and genomic features of patients harboring HLA-I LOH. Human mutation 2021 7 42 (10): 1254-1264. Zhao Jian, Xiao Xiaoxiong, Li Yue, Gao Xuan, Zhang Xiuqin, Liu Zeyi, Yi Yuting, Fu Xiaorui, Wang Han, Guan Yanfang, Xia Xuefeng, Zhang Weixing, Huang Jian' |
| Polymorphisms of Antigen-Presenting Machinery Genes in Non-Small Cell Lung Cancer: Different Impact on Disease Risk and Clinical Parameters in Smokers and Never-Smokers. Frontiers in immunology 2021 6 12 664474. Wi?niewski Andrzej, Sobczy?ski Maciej, Pawe?czyk Konrad, Por?bska Irena, Jasek Monika, Wagner Marta, Niepiek?o-Miniewska Wanda, Kowal Aneta, Dubis Joanna, J?druchniewicz Natalia, Ku?nierczyk Pio |
| Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients. Thoracic cancer 2021 Jun . Gong Lei, He Ronghui, Xu Yanjun, Luo Taobo, Jin Kaixiu, Yuan Wuzhou, Zheng Zengguang, Liu Lanxuan, Liang Zebin, Li Ao, Zheng Zhiguo, Li H |
| A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. Oncogene 2021 Jun . Wu Jie, Li Lan, Zhang Huibo, Zhao Yaqi, Zhang Haohan, Wu Siyi, Xu B |
| Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma. Translational lung cancer research 2021 4 10 (3): 1327-1337. Patiño-García Ana, Guruceaga Elizabeth, Segura Victor, Sánchez Bayona Rodrigo, Andueza Maria Pilar, Tamayo Uria Ibon, Serrano Guillermo, Fusco Juan Pablo, Pajares María José, Gurpide Alfonso, Ocón Marimar, Sanmamed Miguel F, Rodriguez Ruiz Maria, Melero Ignacio, Lozano Maria Dolores, de Andrea Carlos, Pita Guillermo, Gonzalez-Neira Anna, Gonzalez Alvaro, Zulueta Javier J, Montuenga Luis M, Pio Ruben, Perez-Gracia Jose Lu |
| Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Feb . Datar Ila J, Hauc Sacha C, Desai Shruti, Gianino Nicole, Henick Brian, Liu Yuting, Syrigos Kostas, Rimm David L, Kavathas Paula, Ferrone Soldano, Schalper Kurt |
| Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. Journal of cancer research and clinical oncology 2021 12 148 (3): 647-656. Purde Mette-Triin, Niederer Rebekka, Wagner Nikolaus B, Diem Stefan, Berner Fiamma, Hasan Ali Omar, Hillmann Dorothea, Bergamin Irina, Joerger Markus, Risch Martin, Niederhauser Christoph, Lenz Tobias L, Früh Martin, Risch Lorenz, Semela David, Flatz Luk |
| DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer. Frontiers in oncology 2021 10 11 708294. Dai Jiawei, Jiang Minlin, He Kan, Wang Hao, Chen Peixin, Guo Haoyue, Zhao Wencheng, Lu Hui, He Yayi, Zhou Caic |
| New methodology of TMB assessment from tissue and liquid biopsy in NSCLC. PloS one 2022 9 17 (9): e0275121. K?ížová ?udmila, Šafa?íková Markéta, Kalousová Marta, Pfeiferová Lucie, Kub?na Aleš Antonín, Vo?ka Michal, Ulrych Jan, Franková V?ra, Petruželka Luboš, Zima Tomáš, Feltl Dav |
| Sex-specific differences in immunogenomic features of response to immune checkpoint blockade. Frontiers in oncology 2022 12 945798. Scott Susan C, Shao Xiaoshan M, Niknafs Noushin, Balan Archana, Pereira Gavin, Marrone Kristen A, Lam Vincent K, Murray Joseph C, Feliciano Josephine L, Levy Benjamin P, Ettinger David S, Hann Christine L, Brahmer Julie R, Forde Patrick M, Karchin Rachel, Naidoo Jarushka, Anagnostou Valsa |
| Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy. European journal of cancer (Oxford, England : 1990) 2022 Jun 172 98-106. Abed Afaf, Law Ngie, Calapre Leslie, Lo Johnny, Bhat Vikas, Bowyer Samantha, Millward Michael, Gray Elin |
| HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade. Annals of oncology : official journal of the European Society for Medical Oncology 2022 3 33 (7): 728-738. Shao X M, Huang J, Niknafs N, Balan A, Cherry C, White J, Velculescu V E, Anagnostou V, Karchin |
| Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapy. Frontiers in genetics 2022 12 13 1066636. Zhang Xiaotao, Tang Hongzhen, Luo Haitao, Lu Huiping, Pan Chaohu, Yu Haiming, Zhang Linlin, Guan Yaping, Yu Lan, Chu Huili, Chen Jun, Wang J |
| An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. Frontiers in immunology 2022 12 13 1022598. Lin Jing, Liu Jun, Hao Shi-Guang, Lan Bin, Zheng Xiao-Bin, Xiong Jia-Ni, Zhang Ying-Qian, Gao Xuan, Chen Chuan-Ben, Chen Ling, Huang Yu-Fang, Luo Hong, Yi Yu-Ting, Yi Xin, Lu Jian-Ping, Zheng Xiong-Wei, Chen Gang, Wang Xue-Feng, Chen |
| KIR-HLA gene diversities and susceptibility to lung cancer. Scientific reports 2022 Oct 12 (1): 17237. Hematian Larki Marjan, Ashouri Elham, Barani Shaghik, Ghayumi Seiyed Mohammad Ali, Ghaderi Abbas, Rajalingam Ra |
| Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes. Molecular cancer 2023 7 22 (1): 120. Lorraine Dalens, Julie Niogret, Corentin Richard, Sandy Chevrier, Pascal Foucher, Bruno Coudert, Aurélie Lagrange, Laure Favier, Virginie Westeel, Stefano Kim, Olivier Adotevi, Caroline Chapusot, Laurent Martin, Laurent Arnould, Courèche-Guillaume Kaderbhai, Romain Boid |
| Germline variants of the genes involved in NF-kB activation are associated with the risk of COPD and lung cancer development. Acta pharmaceutica (Zagreb, Croatia) 2023 6 73 (2): 243-256. Jurica Baranasic, Yasmeen Niazi, Subhayan Chattopadhyay, Lada Rumora, Lorna ?orak, Andrea Vuki? Dugac, Marko Jakopovi?, Miroslav Samaržija, Asta Försti, Jelena Knežev |
| Association of HLA diversity with the risk of 25 cancers in the UK Biobank. EBioMedicine 2023 5 92 104588. Qiao-Ling Wang, Tong-Min Wang, Chang-Mi Deng, Wen-Li Zhang, Yong-Qiao He, Wen-Qiong Xue, Ying Liao, Da-Wei Yang, Mei-Qi Zheng, Wei-Hua J |
| First-in-human clinical trial results with ABBV-184, a first-in-class T-cell Receptor/Anti-CD3 bispecific protein, in adults with Previously treated AML or NSCLC. Expert review of anticancer therapy 2024 7 . Pierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, Arnaud Pigneux, Junichiro Yuda, Mahipal Sinnollareddy, William R Henner, Diana Chen, Kevin J Freise, Rachel S Leibman, Abraham Avigdor, Toshio Shimi |
| Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A?02-eligible patients. Molecular therapy. Methods & clinical development 2024 6 32 (2): 101265. Tianjiao Wang, Jean-Marc Navenot, Stavros Rafail, Cynthia Kurtis, Mark Carroll, Marian Van Kerckhoven, Sofie Van Rossom, Kelly Schats, Konstantinos Avraam, Robyn Broad, Karen Howe, Ashley Liddle, Amber Clayton, Ruoxi Wang, Laura Quinn, Joseph P Sanderson, Cheryl McAlpine, Carly Carozza, Eric Pimpinella, Susan Hsu, Francine Brophy, Erica Elefant, Paige Bayer, Dennis Williams, Marcus O Butler, Jeffrey M Clarke, Justin F Gainor, Ramaswamy Govindan, Victor Moreno, Melissa Johnson, Janet Tu, David S Hong, George R Blumensche |
| Molecular and immune characterization of Chinese early-stage non-squamous non-small cell lung cancer: a multi-omics cohort study. Translational lung cancer research 2024 5 13 (4): 763-784. Haoxin Peng, Xiangrong Wu, Xiaoli Cui, Shaopeng Liu, Yueting Liang, Xiuyu Cai, Mengping Shi, Ran Zhong, Caichen Li, Jun Liu, Dongfang Wu, Zhibo Gao, Xu Lu, Haitao Luo, Jianxing He, Wenhua Lia |
| Characterization of cell cycle, inflammation, and oxidative stress signaling role in non-communicable diseases: Insights into genetic variants, microRNAs and pathways. Computers in biology and medicine 2024 4 174 108346. Salvatore D'Antona, Danilo Porro, Francesca Gallivanone, Gloria Berto |
| Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer. Scientific reports 2024 1 14 (1): 345. Cindy Y Jiang, Lili Zhao, Michael D Green, Shashidhar Ravishankar, Andrea M H Towlerton, Anthony J Scott, Malini Raghavan, Matthew F Cusick, Edus H Warren, Nithya Ramna |
- Page last reviewed:Feb 1, 2024
- Content source: